Articles On Creso Pharma (ASX:CPH)

Special Report: Diversified cannabis company Creso Pharma (ASX:CPH) is making moves to quickly capitalise on the legalisation of recreational marijuana in America’s fourth-most populous state. New York last week became the 15th US state to...

Creso Pharma (ASX:CPH) has appointed a US Director of Business Development just as New York State has legalised recreational cannabis. New York State is expected to become one of the largest recreational markets in the US valued at US$4.2BN...

Creso Pharma (ASX:CPH) has announced the appointment of John Griese as the director of US business development and welcomed changes that will legalise, tax and regulate recreational cannabis in the state of New York. 

Australian company Creso Pharma (ASX: CPH) has appointed leading cannabis executive John Griese to the role of director of US business development, following a global trend towards cannabis legalisation as well as recent laws in New York st...

Australian medicinal cannabis company Creso Pharma (ASX: CPH) has appointed a director of US business development to capture opportunities in the growing market after New York State legalised recreational marijuana last week. Meanwhile, c...

The Creso Pharma Ltd [ASX:CPH] share price is up 1%, trading at 20.2 cents. The CPH share price exploded higher in December 2020 on a wave of positive news, and looks to be bouncing off the .618 Fibonacci level.. The post Creso Pharma Shar...

The Creso Pharma Ltd (ASX: CPH) share price is edging higher in mid-afternoon trade following its new CBD product launch. At the time of writing, the cannabis company’s shares are trading at 21 cents, up 2.5%. Product launch Investors appe...

The S&P/ASX 200 Index (ASX: JXO) is having a pretty decent day today. A the time of writing, the ASX 200 is up a healthy pre-Easter 0.21%. But one group that is doing a quarter-ounce better are ASX cannabis shares. Take Creso Pharma Lt...

The products are based on second-generation newly developed technology optimising CBD content and taste and provide the company with an opportunity to expand its target consumer base into the mainstream convenience food and beverage market.

As its entry into the psychedelic medicine space progresses, Creso Pharma (ASX: CPH) has continued its cannabinoid product focus with the launch of three CBD-based tea products. The company has unveiled three CBD-based teas which will be so...

Creso Pharma Limited (ASX:CPH; FRA:1X8) has launched its proprietary CBD-based teas products in Switzerland with other European markets, including Germany, earmarked for near-term expansion. Three new products have been launched under the c...

Australia’s medical marijuana industry is showing strong growth, according to an industry-leading biannual report. The Freshleaf Analytics report, released this morning, says that patient numbers have grown 15-fold over the past two and a h...

The Creso Pharma Ltd [ASX:CPH] share price is up after Halucenex enters the deal to produce psychedelic extracts from psilocybin mushrooms. The Creso share price is up 13%... The post Creso Pharma Share Price Up on Halucenex Update (ASX:CP...

The agreement with Advanced Extraction Systems Inc and subsequent fabrication of a leading extraction system will provide Halucenex with a first-mover advantage in terms of psychedelic product and delivery methods.

The mere mention of magic mushrooms, ecstasy or ketamine is enough to send parents of teenagers into conniptions. But are these so-called party drugs poised to follow cannabis into the realm of a medical treatment within a legitimate listed...

Creso Pharma’s (ASX: CPH) soon to be subsidiary Halucenex Life Sciences will have access to high quality psychedelic extracts for its proposed research via an agreement with medical and recreational extraction specialists Advanced Extractio...

Creso Pharma’s (ASX:CPH) pending acquisition of Halucenex Life Sciences should prove to be an astute move, with Halucenex continuing to rapidly move towards its goal of developing and licensing psychedelic compounds for the pharmaceutical a...

The ‘Horizons Marijuana Life Sciences Index ETF’ (HMMJ) — viewed as a benchmark for the North American cannabis industry — entered a downward slide last week despite positive news from New York, after regulators reached a deal that will see...

It wasn’t too long ago that the very idea of ASX cannabis shares was laughable. Aside from a few smoky hash bars in the Netherlands, cannabis use was prosecuted vigorously across most countries. While billions of dollars were earned in glo...

Creso Pharma Ltd [ASX:CPH] share price is down today after releasing details of a capital raise to fund clinical trials and expand offerings. The CPH share price is down 2% this month... The post Creso Pharma Share Price Down on Capital Ra...

Creso Pharma (ASX: CPH) is edging closer to becoming part of our long term portfolio. CPH just raised $18M, which significantly shores up the balance sheet - another tick in the box for us as CPH builds trust to enter our long term portfoli...

Creso Pharma (ASX:CPH) has received firm commitments to raise $18M, a sum that significantly shores up its balance sheet. The company will issue approximately 94.7 million shares at an issue price of 19 cents. Billionaire rich lister John H...

Creso Pharma Ltd (ASX: CPH) shares are falling today after the company received firm commitments to raise A$18 million. At the time of writing, the Creso share price has slumped 6.52% to 21.5 cents. The funds raised will be deployed to und...

Billionaire Rich Lister John Hancock is putting money into ASX-listed cannabis/psychedelics outfit Creso Pharma.

The ASX finished the day slightly in the green, dragged down by tech stocks which lost nearly 1.5 per cent and new float Airtasker (ASX:ART) fell by over 20 per cent. Airtasker debuted at 65 cents and rose over Tuesday and Wednesday to over...

Today on the ASX, small caps had a down day, large caps had a good day while Airtasker (ASX:ART) had another brilliant day. The ASX 200 rose 0.5 per cent to 6,779 points while the ASX Emerging Companies Index fell 1.1 per cent to 2,009 poin...

Source:William Potter, Shutterstock The market opened flat but since then till noon it gained strength, with the benchmark index ASX 200 at 6779.40 points after gaining 34 points, up by 0.50% on previous day closure. Health Care is leadin...

A week since inking a deal to buy a Canadian psychedelics outfit, ASX-listed Creso Pharma is now seeking a fresh injection of cash. 

Ahead of its upcoming post traumatic stress disorder clinical trials, Creso Pharma’s (ASX: CPH) soon to be Canadian psychedelic medicine focused subsidiary Halucenex Life Sciences has secured pharmaceutical grade psilocybin. Creso revealed...

Creso Pharma (ASX:CPH) today announced it is listing on the OTC market in the USA. CPH is on trend with several ASX stocks that have listed on the OTC (Over the Counter) exchange in the US including: Novonix was as high as 152% and is curr...

Creso Pharma (ASX:CPH) is pursuing a secondary listing in the United States as momentum builds for US marijuana reform, and says its Canadian acquisition target has added to its valuable stockpile of synthetic psilocybin. With cannabis lega...

If you’re travelling from Canada, Holland, certain US states, or any other parts of the world where recreational cannabis use has been legalised, step carefully if you plan to visit Japan. Japanese courts continue to enforce strict laws su...

Creso Pharma Limited (ASX:CPH, FRA: 1X8) has announced three new purchase orders for its wholly-owned Canadian subsidiary, Mernova Medicinal Inc, with a total value of C$177,122.40 (A$183,019.55). Included in these purchase orders is the fi...

Creso Pharma (ASX: CPH) has closed out a busy week with news its wholly-owned Canada-based subsidiary Mernova had received three purchase orders worth a combined $183,019. The purchases include the first ever order for Mernova’s Ritual Stic...

The Creso Pharma Ltd (ASX: CPH) share price is trading lower on Friday despite the release of a positive announcement. At the time of writing, the cannabis company’s shares are down over 2% to 22.5 cents. What did Creso Pharma announce? Th...

Closing Bell is Stockhead’s daily recap of the ASX’s biggest movers – the winners and losers alike. Data is taken at the market close – at 4.10pm AEDT. Stocks highlighted in yellow rose (or fell) after making announcements during intraday t...

Australia’s federal government will grant $15M to clinical studies that explore the use of psychedelic drugs like magic mushrooms and ecstasy, to treat Australians with debilitating mental illnesses. This is a crucial breakthrough in the fi...

The market may be tumbling lower again on Thursday, but the same cannot be said for the Creso Pharma Ltd (ASX: CPH) share price. In afternoon trade the cannabis company’s shares are up a sizeable 16% to 22 cents. This gain means the Creso...

Special Report: Just days after Creso Pharma (ASX:CPH) announced it was entering the global market for psychedelic medicine, Australia’s federal government has announced millions in funding for the potential lifesaving therapeutic. While Cr...

Here’s our fortnightly wrap of all the news driving ASX health stocks. It’s been a mixed two weeks for small-cap health companies, with 58 companies gaining ground and 54 losing it. Another 16 were flat. Code Company Price % return...

Pot legalisation is creeping across the US state by state, and a major market could be about to join their ranks. Reports out of New York indicate that lawmakers in the Empire State are close to signing a new bill legalising recreational ca...

The ASX finished in the red today dragged down by resources and energy. Materials and Energy stocks lost over 1 per cent each while Tech was the best sector gaining 0.70 per cent. Large caps fared worse than small caps with the ASX 200 losi...

Creso Pharma Ltd (ASX: CPH) announced today that its target acquisition company Halucenex Life Sciences has made progress in the commencement of a significant phase II clinical trial.   Creso advised that Halucenex has appointed leading re...

Fresh from revealing its proposed acquisition of Canadian psychedelics company Halucenex, Creso Pharma (ASX: CPH) has announced the appointment of a lead investigator for its target’s phase two clinical trial. Creso earlier this week announ...

Creso Pharma Limited’s (ASX:CPH; FRA: 1X8) targeted acquisition company, Halucenex Life Sciences has appointed True North Clinical Research (True North) as the principal investigator for its proposed Phase II Clinical Trial. This trial will...

2021 has served up a rocky start for pot stocks, with investors vacating the speculative sector in favour of other prospects. As can be seen via Creso Pharma Ltd's [ASX:CPH] latest venture, the Creso share price is down 1.42%... The post CP...

If Mexico moves forward with legalising recreational marijuana use, the ripple effects could boost cannabis shares across the globe. ASX cannabis shares, especially those with international markets in their sites, could enjoy a fresh tailw...

The Creso Pharma Ltd (ASX: CPH) share price has slipped in afternoon trading today after the company announced an agreement to acquire Halucenex Life Sciences Inc. The Creso Pharma share price lifted as high as 23 cents just after the mark...

Creso Pharma (ASX: CPH) has announced a transformational move to evolve from a medical cannabis company to an integrated natural medicines provider with the acquisition of Canadian psychedelics company, Halucenex Life Sciences Inc. Halucene...

Creso Pharma (ASX: CPH) is looking to tap into the emerging psychedelics medicine market with the proposed acquisition of Canadian company Halucenex worth more than $7 million. If successful, the deal would give Creso a foothold in the gr...